Hypothyroidism and Hashimoto Disease in Children: Growth, School, and Long-term Outlook

Untreated childhood hypothyroidism affects growth, puberty, and school performance. Newborn screening catches congenital cases. Hashimoto disease in children is rising and requires careful dosing as kids grow. Most children on adequate levothyroxine reach normal adult height.

Why pediatric hypothyroidism is its own problem

Thyroid hormone does in childhood what no other hormone fully replaces: it builds the brain in the first three years of life, sets the pace of linear growth through childhood, and gates the start of puberty. Adults with hypothyroidism feel tired and gain weight; children with untreated hypothyroidism stop growing, fall behind in school, and miss puberty milestones [C1][C2]. The consequences of delay are not symmetrical with the adult case — they can be developmental and, in the newborn period, permanent if untreated [C1][C2].

Pediatric hypothyroidism splits into two distinct entities. Congenital hypothyroidism affects roughly 1 in 2,000 to 1 in 4,000 newborns globally, caused most often by thyroid gland dysgenesis (agenesis, ectopy, or hypoplasia) and less often by inborn errors of hormone synthesis [C1][C2]. Juvenile (acquired) hypothyroidism is overwhelmingly autoimmune — Hashimoto disease — and is the most common endocrine disorder in children after type 1 diabetes [C3][C4]. Its prevalence has risen in many countries over the last two decades [C3].

The clinical pattern by age

Newborn period. Congenital hypothyroidism is usually silent at birth — the placenta supplies enough maternal thyroid hormone to mask the deficit for days to weeks [C1]. That is why every developed country runs universal newborn screening on day 2 to 5 of life via dried blood-spot TSH and/or T4. A screen-positive result triggers confirmatory venous TSH and free T4, and treatment starts within the first 2 weeks of life — ideally before day 14 [C1][C2]. Late-detected cases (after 4 weeks) carry measurable IQ loss; early-treated cases reach normal IQ [C1].

Infancy and early childhood. Signs that should prompt thyroid testing include poor feeding, constipation, prolonged jaundice, a large posterior fontanelle, hypotonia, umbilical hernia, and delayed motor milestones [C1][C2].

School-age and adolescence. Juvenile Hashimoto disease typically presents with one or more of: slowed growth velocity (the most reliable early sign), goiter, weight gain disproportionate to height gain, fatigue, declining school performance, constipation, cold intolerance, dry skin and hair, delayed puberty, or menstrual irregularity in older girls [C3][C4]. Hashimoto is two to three times more common in girls and peaks in early adolescence [C3][C4].

Dose calculation by weight

Pediatric levothyroxine dosing is weight-based and age-banded, not the flat adult formula. Approximate starting ranges from the consensus guidelines [C1][C2][C5]:

Age	Levothyroxine starting dose
0–3 months (congenital)	10–15 mcg/kg/day
3–12 months	6–10 mcg/kg/day
1–5 years	4–6 mcg/kg/day
6–10 years	3–5 mcg/kg/day
11–18 years	2–4 mcg/kg/day
Adult	1.6 mcg/kg/day

Two practical notes. First, the newborn dose is intentionally high — the goal is to normalize free T4 within 2 weeks and TSH within the first month, because the developing brain is hormone-dependent [C1]. Second, dose per kilogram falls steadily through childhood as growth velocity slows; using an adult formula in a teenager will under-dose them [C1][C5].

Monitoring during growth and puberty

Frequency of testing is higher in children than in adults. After dose initiation or change, repeat TSH and free T4 at 4 to 6 weeks. Once stable, the consensus recommends [C1][C2]:

• 0–6 months: every 1–2 months
• 6 months to 3 years: every 2–4 months
• 3 years to puberty: every 3–6 months
• Through puberty: every 4–6 months, with extra checks around growth spurts

Puberty raises levothyroxine requirements in many children — total body mass increases, and estrogen (in girls) raises thyroxine-binding globulin, which lowers free hormone availability [C5]. A dose that was correct at age 11 is frequently too low at 13. Endocrinologists track growth velocity, Tanner stage, and TSH together; a child who is growing well, hitting puberty milestones, and has a TSH in the age-appropriate range is on the right dose [C1][C2].

What recovers on adequate levothyroxine

Most pediatric symptoms reverse with adequate replacement [C1][C2][C5]:

• Growth velocity: catch-up growth begins within months and continues for 1–2 years; most children reach their genetic target height
• Cognition and school performance: improves within months in juvenile cases; preserved from birth in screen-detected congenital cases treated within 2 weeks
• Energy and concentration: usually noticeable within weeks
• Skin, hair, constipation, cold intolerance: resolve over 3–6 months
• Puberty: resumes once euthyroidism is restored

Final adult height in screen-detected, adequately treated congenital hypothyroidism is normal in the great majority of children [C1]. Juvenile Hashimoto, when caught before bone age is severely delayed, also has an excellent height prognosis [C3][C5].

When school performance does not improve

A child whose grades and concentration do not recover after TSH normalizes deserves a careful re-look [C1][C3][C5]:

1. Adherence. Levothyroxine taken inconsistently or with food/calcium/iron will not normalize free T4 even if TSH looks borderline. Reconfirm the daily routine.
2. Under-dosing for current weight. Recheck TSH against the age-appropriate range and adjust by weight, not by adult target.
3. Comorbid attention or learning difference. Hashimoto disease and ADHD/learning disorders can co-exist; one does not explain the other. Educational assessment is reasonable.
4. Sleep, iron, vitamin D. Iron deficiency, low vitamin D, and disordered sleep are common and easy to miss. See our iron-deficiency-thyroid and vitamin-d-hashimotos articles.
5. Anxiety and depression. Adolescent Hashimoto patients have higher rates of mood symptoms even when euthyroid; mental-health support is part of standard care [C3][C4].

When to defer treatment in subclinical pediatric cases

Not every elevated TSH in a child needs immediate levothyroxine. Pediatric subclinical hypothyroidism (TSH 5–10 mIU/L with normal free T4) is common, often transient, and most cases resolve or remain stable without treatment over 2–5 years of follow-up [C1][C3]. Endocrinologists typically reserve treatment for [C1][C5]:

• TSH consistently above 10 mIU/L
• Goiter present
• Positive anti-TPO or anti-Tg antibodies (Hashimoto pattern)
• Slowing growth velocity or pubertal delay
• Symptoms attributable to hypothyroidism

Mild, isolated TSH elevation in an otherwise growing, asymptomatic child without antibodies is often monitored every 6–12 months [C1][C3]. Over-treatment of children carries real risk — over-replacement can accelerate bone age and compromise final height, and is associated with cardiovascular and bone effects in adults [C5][C7].

What does NOT help

Some heavily promoted approaches lack evidence in children [C5][C6]:

• Iodine supplementation in iodine-sufficient countries — in Hashimoto disease, excess iodine can worsen autoimmune destruction. See our iodine-hypothyroidism article.
• Selenium for routine pediatric Hashimoto — adult trials are mixed and pediatric data are sparse; not standard of care [C3].
• Gluten-free or "autoimmune protocol" diets in non-celiac children — no evidence of effect on growth or thyroid function; risk of nutritional gaps in a growing child.
• Desiccated thyroid or T3-only formulations as first-line — pediatric and adult guidelines recommend levothyroxine [C1][C5].
• Skipping doses or stopping during summer — even short interruptions disturb growth and school re-entry. Daily, consistent dosing is non-negotiable [C1][C5].

Practical guidelines

1. Ensure newborn screening was completed and documented, especially for children born outside the United States, Canada, or Western Europe. A missing screen is the single most preventable cause of delayed diagnosis [C1][C2].
2. Give the dose on an empty stomach, separated from food, calcium, iron, and soy formula by 30–60 minutes [C1][C5]. Crushed tablets in a small amount of water or breast milk are acceptable for infants per the consensus guidelines [C1].
3. Track height and weight at every visit — a falling growth percentile is often the first sign of under-dosing or non-adherence [C1][C3].
4. Recheck labs after every dose change at 4–6 weeks and at least every 6 months once stable [C1][C2].
5. Plan for the puberty dose-up — most teens need an upward dose adjustment between ages 11 and 14 [C1][C5].
6. Build a transition plan to adult care between ages 16 and 19 — handover to an adult endocrinologist with a written summary of diagnosis, dose history, antibody status, and target TSH range protects continuity [C1][C5].

Frequently asked questions

Will my child be on levothyroxine for life? For congenital hypothyroidism with thyroid dysgenesis or for confirmed Hashimoto disease with antibodies, yes — treatment is lifelong [C1][C2][C3]. In transient congenital hypothyroidism (some preterm or maternal-antibody cases), a trial off treatment is offered around age 3 with re-testing [C1].

Can my child play sports and live normally? Yes. A child on adequate, stable levothyroxine has no activity restrictions, no special diet beyond the empty-stomach dosing rule, and no extra medical limitations [C1][C5][C6].

Why does the dose keep going up? Children grow. Total body mass, organ size, and protein-binding all increase, so the daily dose follows weight and developmental stage rather than staying fixed [C1][C5].

Is Hashimoto disease really more common now? Pediatric Hashimoto prevalence has measurably risen in multiple countries over the last 20 years; the reasons are debated and include better detection, iodine intake shifts, and broader autoimmune trends [C3][C4].

What about subclinical hypothyroidism — should we treat or wait? Most mild, isolated cases without antibodies, goiter, or growth slowdown are monitored rather than treated; persistent TSH above 10, positive antibodies, or slowing growth tip toward treatment [C1][C3][C5].

Bottom line

Pediatric hypothyroidism is a treatable condition with an excellent prognosis when caught early and dosed correctly [C1][C2]. Newborn screening protects the congenital cases from cognitive harm; juvenile Hashimoto disease responds to weight-based levothyroxine that is re-titrated at growth spurts and through puberty [C1][C3][C5]. Most children reach normal adult height, normal school performance, and normal pubertal milestones on adequate replacement [C1][C3]. The two biggest risks are missed screening at birth and under-dosing as a child grows — both are preventable with regular monitoring and a clear handover to adult care [C1][C5].

Sources

1. [C1] van Trotsenburg P, Stoupa A, Léger J, et al. Congenital Hypothyroidism: A 2020–2021 Consensus Guidelines Update. Thyroid. 2021;31(3):387–419. PubMed: 33272083
2. [C2] Léger J, Olivieri A, Donaldson M, et al. European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. J Clin Endocrinol Metab. 2014;99(2):363–384. PubMed: 24446653
3. [C3] Oktaviana M et al. Evaluation of Characteristics in Children and Adolescents with Hashimoto Thyroiditis in Euthyroid and Hypothyroid Phases: A Systematic Review and Meta-analysis. 2025. PubMed: 42044441
4. [C4] Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014;13(4-5):391–397. PubMed: 24434360
5. [C5] Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism. Thyroid. 2014;24(12):1670–1751. PubMed: 25266247
6. [C6] American Thyroid Association. Hypothyroidism — Patient Information. thyroid.org
7. [C7] Baskaran BS et al. Risk of cardiac, neuropsychiatric and musculoskeletal adverse events with levothyroxine: Systematic review. 2026. PubMed: 41559017

---

For educational purposes only. Not medical advice. Always consult your healthcare provider.